The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...
- Findings from the RELIEF study in France showed for the first time, in the largest retrospective analysis of its kind of nearly 75,000 people living with diabetes, use of the FreeStyle Libre system ...
At least seven fires and one injury that were related to some FreeStyle Libre glucose monitor products have led the US Food and Drug Administration to issue a Class I recall, the agency's strongest, ...
ABBOTT PARK, Ill., Sept. 27, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the FreeStyle ® Libre Flash Glucose Monitoring System ...
Use of the novel FreeStyle Libre glucose monitoring system (Abbott) leads to improved glycemic control among people with diabetes, new real-world data indicate. Findings from deidentified data for ...
ABBOTT PARK, Ill., Sept. 3, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it has received CE Mark (Conformite Europeenne) for its FreeStyle ® Libre Flash Glucose Monitoring System, a ...
Zacks.com on MSN
Growing Diagnostics Arm Supports ABT Stock, Macro Issues Ail
ABT gains momentum with strong FreeStyle Libre sales and Diagnostics growth but global macro headwinds weigh on performance.
MISSISSAUGA, ON, Dec. 17, 2024 /CNW/ -- Abbott (NYSE: ABT) today announced that the Government of Alberta has added Abbott's FreeStyle Libre 2 * flash glucose monitoring system to the Alberta Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback